IBIO, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
IBIO, INC. (IBIO) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$18.38 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-09-05
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$5.16M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$4.86M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$4.36M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$3.99M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$18.38M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$15.44M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$29.31M.
- IBIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$29.51M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-05 | -$10.02M derived: sum of 2 quarters · filed 2025-09-05 | -$14.39M derived: sum of 3 quarters · filed 2025-09-05 | -$18.38M 10-K · filed 2025-09-05 |
| 2025-03-31 | -$4.86M 10-Q · filed 2025-05-02 | -$9.22M derived: sum of 2 quarters · filed 2025-05-02 | -$13.21M 10-Q · filed 2025-05-02 | -$16.46M derived: sum of 4 quarters · filed 2025-09-05 |
| 2024-12-31 | -$4.36M 10-Q · filed 2025-02-10 | -$8.35M 10-Q · filed 2025-02-10 | -$11.60M derived: sum of 3 quarters · filed 2025-09-05 | -$14.23M derived: sum of 4 quarters · filed 2025-09-05 |
| 2024-09-30 | -$3.99M 10-Q · filed 2024-11-12 | -$7.24M derived: sum of 2 quarters · filed 2025-09-05 | -$9.87M derived: sum of 3 quarters · filed 2025-09-05 | -$14.36M derived: sum of 4 quarters · filed 2025-09-05 |
| 2024-06-30 | -$3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-05 | -$5.88M derived: sum of 2 quarters · filed 2025-09-05 | -$10.37M derived: sum of 3 quarters · filed 2025-09-05 | -$15.44M 10-K · filed 2025-09-05 |
| 2024-03-31 | -$2.63M 10-Q · filed 2025-05-02 | -$7.12M derived: sum of 2 quarters · filed 2025-05-02 | -$12.20M 10-Q · filed 2025-05-02 | -$17.13M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | -$4.49M 10-Q · filed 2025-02-10 | -$9.56M 10-Q · filed 2025-02-10 | -$14.49M derived: sum of 3 quarters · filed 2025-02-10 | -$20.77M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-09-30 | -$5.07M 10-Q · filed 2024-11-12 | -$10.01M derived: sum of 2 quarters · filed 2024-11-12 | -$16.29M derived: sum of 3 quarters · filed 2024-11-12 | -$26.85M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$4.93M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-24 | -$11.21M derived: sum of 2 quarters · filed 2024-09-24 | -$21.77M derived: sum of 3 quarters · filed 2024-09-24 | -$29.31M 10-K/A · filed 2024-09-24 |
| 2023-03-31 | -$6.28M 10-Q · filed 2023-05-15 | -$16.84M derived: sum of 2 quarters · filed 2023-05-19 | -$24.38M 10-Q · filed 2023-05-15 | -$34.77M derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-12-31 | -$10.56M 10-Q/A · filed 2023-05-19 | -$18.10M 10-Q/A · filed 2023-05-19 | -$28.49M derived: sum of 3 quarters · filed 2023-09-27 | -$35.23M derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-09-30 | -$7.54M 10-Q · filed 2022-11-14 | -$17.92M derived: sum of 2 quarters · filed 2023-09-27 | -$24.67M derived: sum of 3 quarters · filed 2023-09-27 | -$31.86M derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-06-30 | -$10.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | -$17.13M derived: sum of 2 quarters · filed 2023-09-27 | -$24.32M derived: sum of 3 quarters · filed 2023-09-27 | -$29.51M 10-K · filed 2023-09-27 |
| 2022-03-31 | -$6.75M 10-Q · filed 2023-05-15 | -$13.94M derived: sum of 2 quarters · filed 2023-05-19 | -$19.13M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | -$7.19M 10-Q/A · filed 2023-05-19 | -$12.38M 10-Q/A · filed 2023-05-19 | ||
| 2021-09-30 | -$5.19M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |